Clearside Biomedical (NASDAQ:CLSD) specializes in the development of innovative therapies for eye diseases. Their focus is on creating treatments that can be administered via their proprietary SCS Microinjector, a device designed to deliver medications directly to the back of the eye. Their projects primarily target conditions such as uveitis, diabetic macular edema, and retinal vein occlusion. Clearside's objective is to improve the lives of patients suffering from vision-threatening disorders by offering less invasive and more effective treatment options. They are committed to advancing their research and development to broaden their pipeline of drug candidates and fulfill unmet medical needs within the ophthalmology community.